The Biotech Exit Playbook: What Acquirers Actually Look For

Published 14 May 2026. Giuseppina Sannino, PhD.

Most biotech founders think about exit in the months before. The successful ones think about it in the years before. Lower valuations, unfavorable deal structures, and due diligence problems that could have been fixed: the cost of preparing late shows up directly in deal outcomes.

What acquirers actually look for

Strategic fit beyond technology
Technology alone rarely justifies acquisition. Acquirers look for strategic alignment: how the target fits their pipeline, geography, customer base or competitive position. Identifying your 5-10 strategic acquirers years before exit, and building toward fit, is one of the highest-leverage activities a biotech leadership team can do.


Clean, defensible data
A surprising number of deals fall through during due diligence not because of bad data, but because of disorganized data. Inconsistent versions, missing contracts, undocumented decisions, marketing claims unsupported by underlying evidence. A clean data room signals operational maturity. A messy one signals risk.


Predictable commercial traction

Acquirers and investors look at different signals. Recurring revenue, customer concentration, contract structure, sales cycle predictability: these matter more to acquirers than total revenue. A customer concentration of 30% or more is a red flag. A sales cycle of 18+ months is a red flag. These are fixable, but they take time.

When to start preparing

The honest answer: 3 to 5 years before exit.

Years 1–2: identify strategic acquirers, structure data room foundations, align commercial growth with acquisition signals.

Years 3–4: build direct relationships with target acquirers, address IP and contractual gaps.

Final year: formal preparation with boutique M&A advisors.

Most founders compress this into 6 to 12 months. The compression is visible in deal outcomes.

How Auralis EXIT supports companies

EXIT supports biotech and life sciences companies preparing for acquisition, partnership, or strategic transition. Our work covers:

  • Strategic acquirer mapping: identification and relationship-building with target acquirers years before a process
  • Commercial narrative for M&A: positioning the company's traction and IP for acquisition conversations
  • M&A advisory access: introduction to boutique M&A advisors through our partner network

Exit preparation is designed around your timeline, asset structure, and target outcome.

Discuss your exit preparationTake the Free Market Readiness Audit